Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 28;5(3):100665.
doi: 10.1016/j.jhepr.2022.100665. eCollection 2023 Mar.

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)

Fabienne Marcellin  1 , Abbas Mourad  1 , Maud Lemoine  2 , Charles Kouanfack  3   4 , Moussa Seydi  5 , Patrizia Carrieri  1 , Alain Attia  6 , Camelia Protopopescu  1 , Karine Lacombe  7   8 , Sylvie Boyer  1
Affiliations

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)

Fabienne Marcellin et al. JHEP Rep. .

Abstract

Background & aims: Patient-reported outcomes (PROs) are poorly documented for patients with chronic hepatitis C on direct-acting antiviral (DAA) treatment in low-to-middle-income countries. We documented PROs during and after DAA treatment in participants of the TAC ANRS 12311 trial (West and Central Africa).

Methods: Trial participants received a 12-week regimen containing either sofosbuvir plus ribavirin (HCV genotype 2, n = 40), or sofosbuvir plus ledipasvir (HCV genotypes 1 and 4, n = 80). Health-related quality of life (SF-12), fatigue (Piper Fatigue scale), and self-reported symptoms (35-symptom list) were assessed at enrolment (Week (W) 0), during treatment (W2, W4, W8 and W12) and after treatment (W24 and W36). These PROs were compared between W0 and W36 (Wilcoxon signed-rank or McNemar tests). Mixed-effects linear regression models helped identify correlates of physical and mental quality of life component summaries (PCS and MCS) in a longitudinal analysis.

Results: Most PROs were significantly improved 24 weeks after treatment end (W36), without significant differences between treatment groups. For the post-treatment period, multivariable analysis showed significant increases in PCS for patients with cirrhosis and in MCS for patients in the sofosbuvir plus ribavirin group. A higher number of self-reported symptoms at W0 was associated with lower PCS and MCS, older age and cirrhosis with lower PCS, and male sex and HCV cure with higher PCS.

Conclusions: Sofosbuvir-based DAA therapy was associated with a significant improvement in PROs 6 months after treatment end in patients with chronic HCV infection from Central and West Africa. These findings may guide HCV treatment providers in low-to-middle-income countries to deliver pre-treatment information concerning the benefits of DAAs beyond viral eradication.

Clinicaltrialsgov identifier: NCT02405013.

Impact and implications: Perceptions and experiences (i.e. "patient-reported outcomes") of patients with chronic hepatitis C receiving direct-acting antivirals (DAAs) are poorly documented in the African setting. This study shows significant improvements in health-related quality of life, fatigue, and self-reported symptoms 24 weeks after the end of a 12-week sofosbuvir-based DAA regimen in 120 patients from Central and West Africa. These findings substantially add to the body of knowledge about DAA therapy in the African setting. Treatment providers should be encouraged to inform patients of the benefits of DAAs beyond viral eradication, to increase treatment adherence and retention in care.

Keywords: DAA, direct-acting antiviral; EOT, end-of-treatment; HRQL, health-related quality of life; LMICs, low-to-middle income countries; MCS, mental component summary; MOS SF-12, Medical Outcomes Study 12-item short-form general health survey; MOS, Medical Outcomes Study; PCS, physical component summary; PROs, patient-reported outcomes; SOF/LDV, sofosbuvir plus ledipasvir; SOF/RBV, sofosbuvir plus ribavirin; SVR, sustained virological response; W, week; WHO, World Health Organization; West Africa; direct-acting antivirals; health-related quality of life; hepatitis C; symptoms.

PubMed Disclaimer

Conflict of interest statement

KL received personal fees for advisory boards and conferences from MSD, Gilead, Abbvie and ViiV Healthcare. PC received research grants by MSD and Intercept unrelated to this work. The other authors declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Symptoms reported by more than 20% of patients at W0: Prevalence rates at W0 and W36 (ANRS 12311 TAC trial, N = 120). W, week.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO . Advocacy Brief; May 2016. Combating hepatitis B and C to reach elimination by 2030. 2016.
    1. WHO . 2016. Global health sector strategy on viral hepatitis 2016–2021 - towards ending viral hepatitis.
    1. Cooke G.S., Andrieux-Meyer I., Applegate T.L., Atun R., Burry J.R., Cheinquer H., et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology commission. Lancet Gastroenterol Hepatol. 2019;4:135–184. - PubMed
    1. Zoratti M.J., Siddiqua A., Morassut R.E., Zeraatkar D., Chou R., van Holten J., et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18 - PMC - PubMed
    1. Pol S., Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations.”. Liver Int. 2018;38:28–33. - PubMed

Associated data